IRB #

STUDY00016851

Title

M16-300: A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer

Principal Investigator

Matthew Taylor

Study Purpose

To assess the safety of rovalpituzumab tesirine when given in combination with nivolumab or nivolumab and ipilimumab in people with extensive-stage small cell lung cancer (SCLC)

Medical Condition(s)

Small cell lung cancer (SCLC)

Eligibility Criteria

1. Confirmed diagnosis of extensive-stage small cell lung cancer (SCLC).
2. Must have had your disease worsen after at least one platinum-based chemotherapy.
3. Must have sufficient performance status and bone marrow function.

Other inclusion criteria may apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Subjects will receive study treatment for as long as their cancer is not getting worse and they do not have any significant side effects.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

AbbVie, Inc.

Recruitment End

03/31/2022

Compensation Provided

No


Go Back